Attention Biotech Investors: Mark Your Calendar For Dec. PDUFA Dates

The U.S. Food and Drug Administration's approval machinery churned out a lot of disappointments in November. Most of the negative verdicts were tied to difficulties the agency had in inspecting facilities where drugs are being manufactured.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.